Pictet Asset Management Holding SA Has $3.39 Million Stake in Natera, Inc. (NASDAQ:NTRA)

Pictet Asset Management Holding SA reduced its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 94.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 21,418 shares of the medical research company's stock after selling 364,069 shares during the quarter. Pictet Asset Management Holding SA's holdings in Natera were worth $3,390,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Principal Securities Inc. increased its stake in Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after buying an additional 59 shares during the period. Gladstone Institutional Advisory LLC raised its position in Natera by 1.7% in the 4th quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company's stock valued at $574,000 after purchasing an additional 61 shares in the last quarter. Silver Oak Securities Incorporated lifted its stake in Natera by 3.1% in the fourth quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company's stock worth $470,000 after acquiring an additional 89 shares during the last quarter. Blue Trust Inc. lifted its position in shares of Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after purchasing an additional 97 shares during the last quarter. Finally, Hanseatic Management Services Inc. lifted its holdings in Natera by 12.0% during the 4th quarter. Hanseatic Management Services Inc. now owns 998 shares of the medical research company's stock worth $158,000 after buying an additional 107 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several research firms have issued reports on NTRA. Canaccord Genuity Group restated a "buy" rating and issued a $180.00 price objective on shares of Natera in a research note on Wednesday, February 26th. Guggenheim raised their price target on Natera from $170.00 to $200.00 and gave the stock a "buy" rating in a research note on Friday, January 17th. Royal Bank of Canada started coverage on Natera in a research note on Thursday, March 13th. They issued an "outperform" rating and a $251.00 price objective for the company. Morgan Stanley raised their target price on shares of Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Finally, Robert W. Baird lifted their target price on shares of Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a report on Friday, February 28th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, Natera has an average rating of "Moderate Buy" and a consensus target price of $178.12.

Natera Trading Up 14.9 %

Shares of Natera stock traded up $19.74 on Wednesday, reaching $151.97. 2,969,764 shares of the company were exchanged, compared to its average volume of 1,390,236. Natera, Inc. has a fifty-two week low of $83.13 and a fifty-two week high of $183.00. The stock has a fifty day moving average price of $153.85 and a 200-day moving average price of $151.75. The firm has a market capitalization of $20.54 billion, a price-to-earnings ratio of -86.35 and a beta of 1.80. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $476.10 million during the quarter, compared to analysts' expectations of $447.91 million. On average, analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Insider Activity at Natera

In other Natera news, insider Solomon Moshkevich sold 24,861 shares of the firm's stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $4,101,319.17. Following the transaction, the insider now directly owns 140,684 shares of the company's stock, valued at approximately $23,208,639.48. This trade represents a 15.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Michael Burkes Brophy sold 25,931 shares of the stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $4,277,837.07. Following the completion of the sale, the chief financial officer now owns 109,665 shares in the company, valued at $18,091,435.05. This represents a 19.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 325,922 shares of company stock worth $51,603,664 over the last three months. Company insiders own 7.60% of the company's stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.